Actionable disease insights from bedside-to-bench investigation in fibrodysplasia ossificans progressiva.
作者信息
Wein Marc N, Yang Yingzi
机构信息
Endocrine Unit, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, United States.
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA 02115, United States.
出版信息
J Bone Miner Res. 2024 May 2;39(4):375-376. doi: 10.1093/jbmr/zjae044.
Abstract
摘要
相似文献
1
Actionable disease insights from bedside-to-bench investigation in fibrodysplasia ossificans progressiva.
J Bone Miner Res. 2024 May 2;39(4):375-376. doi: 10.1093/jbmr/zjae044.
2
A familial case of fibrodysplasia ossificans progressiva (myositis ossificans progressiva).
Trop Doct. 1998 Apr;28(2):108-9. doi: 10.1177/004947559802800222.
3
Challenges in the diagnosis of fibrodysplasia ossificans progressiva with the ACVR1 mutation (c.774G > C, p.R258S): a case report and review of literature.
Orphanet J Rare Dis. 2024 Sep 30;19(1):360. doi: 10.1186/s13023-024-03363-y.
4
Exoneration of NF-kappaB dysregulation in fibrodysplasia ossificans progressiva.
Clin Orthop Relat Res. 2003 Jan(406):205-13. doi: 10.1097/01.blo.0000030075.92399.11.
5
Characterization of bone morphogenetic protein 4 receptor in fibrodysplasia ossificans progressiva.
Clin Orthop Relat Res. 1998 Jan(346):38-45.
6
Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.
Dis Model Mech. 2020 Sep 21;13(9):dmm046441. doi: 10.1242/dmm.046441.
7
Fibrodysplasia ossificans progressiva (stone man syndrome): a case report.
J Med Case Rep. 2019 Dec 1;13(1):364. doi: 10.1186/s13256-019-2297-z.
8
[Fibrodysplasia ossificans progressiva].
Harefuah. 1984 Aug;107(3-4):73-5.
9
Fibrodysplasia ossificans progressiva: Histopathological implications of aberrant bone morphogenic protein signalling for CNS dysgenesis.
Neuropathol Appl Neurobiol. 2022 Jun;48(4):e12805. doi: 10.1111/nan.12805. Epub 2022 Mar 10.
10
Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).
Bone. 2008 Sep;43(3):427-33. doi: 10.1016/j.bone.2008.05.013. Epub 2008 May 28.
引用本文的文献
1
FOP: From Biomolecules to Hope.
Biomolecules. 2025 Feb 24;15(3):328. doi: 10.3390/biom15030328.
2
Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe.
Biomolecules. 2024 Aug 15;14(8):1009. doi: 10.3390/biom14081009.
本文引用的文献
1
Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
J Bone Miner Res. 2024 May 2;39(4):382-398. doi: 10.1093/jbmr/zjae029.
2
Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.
JBMR Plus. 2023 Oct 19;7(12):e10821. doi: 10.1002/jbm4.10821. eCollection 2023 Dec.
3
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Nat Med. 2023 Oct;29(10):2615-2624. doi: 10.1038/s41591-023-02561-8. Epub 2023 Sep 28.
4
Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
J Bone Miner Res. 2023 Mar;38(3):381-394. doi: 10.1002/jbmr.4762. Epub 2023 Jan 25.
5
The gelatinases, matrix metalloproteinases 2 and 9, play individual roles in skeleton development.
Matrix Biol. 2022 Nov;113:100-121. doi: 10.1016/j.matbio.2022.10.002. Epub 2022 Oct 17.
6
Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine.
J Clin Med. 2021 Dec 13;10(24):5821. doi: 10.3390/jcm10245821.
7
Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes.
Nat Commun. 2021 Jun 9;12(1):3505. doi: 10.1038/s41467-021-23556-4.
8
Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.
Sci Transl Med. 2016 Nov 23;8(366):366ra163. doi: 10.1126/scitranslmed.aaf1090.
9
Location-dependent heterotopic ossification in the rat model: The role of activated matrix metalloproteinase 9.
J Orthop Res. 2016 Nov;34(11):1894-1904. doi: 10.1002/jor.23216. Epub 2016 Mar 14.
10
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Sci Transl Med. 2015 Sep 2;7(303):303ra137. doi: 10.1126/scitranslmed.aac4358.
Zotero 插件